

## Fluorodeoxyglucose Positron Emission Tomography Imaging in *Pneumocystis jiroveci* Pneumonia

### Abstract

Fever or pyrexia of unknown origin (PUO) is commonly defined as body temperature higher than 38.3°C on several occasions for a period of at least 3 weeks with uncertain diagnosis after initial routine obligatory investigations. In most cases of PUO, there is an uncommon presentation of a common disease which includes infection, noninfectious inflammatory diseases, malignancy, and miscellaneous causes. We present an interesting case of a 48-year-old man with PUO, who is a known case of multiple myeloma on immunosuppressive therapy, where 18F-fluorodeoxyglucose positron emission tomography-computed tomography was able to detect occult cause of infective etiology.

**Keywords:** 18F-fluorodeoxyglucose, *Pneumocystis carinii*, *Pneumocystis jiroveci* pneumonia, positron emission tomography-computed tomography, pyrexia of unknown origin

**Hemant Rathore,  
Nirav Thaker<sup>1</sup>,  
Inder Talwar<sup>1</sup>**

Departments of Nuclear  
Medicine and PET CT and  
<sup>1</sup>Radiodiagnosis, Bombay  
Hospital and Medical  
Research Centre, Mumbai,  
Maharashtra, India

### Background and Procedure

We describe a case of a 48-year-old man with pyrexia of unknown origin (PUO), who is a known case of multiple myeloma on immunosuppressive therapy, with remission of disease on recent bone marrow examination. This case presented with dry cough and fever over 4 weeks (100°F–102°F) and had an oxygen saturation of 97% on ambient air. The blood tests apart from mild leukopenia were fairly unremarkable. The chest radiography revealed subtle bilateral lung ground-glass opacities and referred for fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomographic (CT) scan to rule out the cause. The FDG-PET scan [Figure 1] revealed diffuse increased metabolic activity in bilateral lungs; the corresponding fused high-resolution CT (HRCT) images showed the acute lung changes in the form of hypermetabolic ill-defined confluent ground-glass opacities with interstitial thickening and crazy paving appearance near completely involving bilateral lungs along with mild bronchial and bronchiolar dilatation [Figure 2]. The imaging was suggestive of acute atypical pneumonia which was further

investigated by bronchoalveolar lavage cytological examination and culture which demonstrated *Pneumocystis jiroveci*.

Pneumocystic jiroveci pneumonia (PJP), is also known as pneumocystic pneumonia or formerly pneumocystic carinii pneumonia, is caused by the ubiquitous unicellular eukaryote, *P jiroveci*, which is a rare cause of infection in the general population, but it is a more frequent cause of morbidity and mortality in immunocompromised persons who are especially with HIV AIDS, postorgan-transplant recipients, and those receiving long-term cytotoxic or steroid therapy, hematological malignancies, as well as other malignancies.<sup>[1]</sup> PJP is classified as a fungal pneumonia but does not respond to antifungal therapy. These patients have a long clinical course over months to years, with stable symptoms and radiographic abnormalities corresponding to pathologic findings of traction bronchiectasis, honeycombing, and interstitial fibrosis.

In a study of 105 pneumocystic pneumonia immunocompromised patients, chest radiographic findings were divided into three stages: early stage; normal or nearly normal chest radiograph, mid-stage; bilateral pulmonary infiltrates, and late stage; bilateral pulmonary consolidation. Chest HRCT findings were also divided into three

### Address for correspondence:

Dr. Hemant Rathore,  
Department of Nuclear  
Medicine and PET CT,  
Bombay Hospital and Medical  
Research Centre, 12 Marine  
Lines, Mumbai - 400 020,  
Maharashtra, India.  
E-mail: hemant.  
nuclearmedicine@gmail.com

Received: 15-09-2021

Accepted: 04-10-2021

Published: 08-07-2022

### Access this article online

Website: www.ijnm.in

DOI: 10.4103/ijnm.ijnm\_140\_21

### Quick Response Code:



**How to cite this article:** Rathore H, Thaker N, Talwar I. Fluorodeoxyglucose Positron Emission Tomography Imaging in *Pneumocystis jiroveci* Pneumonia. Indian J Nucl Med 2022;37:194-5.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow\_reprints@wolterskluwer.com




**Figure 1: Whole-body fluorodeoxyglucose positron emission tomography scan maximum intensity projection image reveals diffuse increased metabolic activity in bilateral lungs with physiological fluorodeoxyglucose uptake in rest of the visualized body**

stages: early stage; bilateral diffuse ground-glass opacity, mid-stage; bilateral diffuse ground-glass opacity with patchy consolidations, and late stage; bilateral diffuse consolidation).<sup>[2]</sup>

### Conclusion

FDG-PET/CT imaging is a very sensitive diagnostic modality for the evaluation of fever of unknown origin by facilitating anatomical localization of focally increased FDG uptake and thereby guiding further diagnostic tests to achieve a final diagnosis.<sup>[3]</sup> Few studies suggest that FDG-PET scan have an important role to play in the diagnosis and monitoring treatment response of pneumocystic pneumonia in the immunocompromised patients.<sup>[4]</sup>



**Figure 2: High-resolution computed tomography (left), and fused fluorodeoxyglucose positron emission tomography and high-resolution computed tomography (right) images reveals hypermetabolic ill-defined confluent ground-glass opacities with interstitial thickening near completely involving bilateral lungs**

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### References

1. Bollée G, Sarfati C, Thiery G, Bergeron A, de Miranda S, Menotti J, et al. Clinical picture of *Pneumocystis jiroveci* pneumonia in cancer patients. *Chest* 2007;132:1305-10.
2. Mu XD, Jia P, Gao L, Su L, Zhang C, Wang RG, et al. Relationship between radiological stages and prognoses of pneumocystis pneumonia in non-AIDS immunocompromised patients. *Chin Med J (Engl)* 2016;129:2020-5.
3. Kouijzer IJ, Mulders-Manders CM, Bleeker-Rovers CP, Oyen WJ. Fever of unknown origin: The value of FDG-PET/CT. *Semin Nucl Med* 2018;48:100-7.
4. Win Z, Todd J, Al-Nahhas A. FDG-PET imaging in *Pneumocystis carinii* pneumonia. *Clin Nucl Med* 2005;30:690-1.